ENTITY
Shanghai Haohai Biological Technology

Shanghai Haohai Biological Technology (6826 HK)

136
Analysis
Health Care • China
Shanghai Haohai Biological Technology engages in the research, development, manufacture, and sale of biomedical materials and pharmaceutical products. The company focuses on therapeutic areas including ophthalmology, medical aesthetics and wound care, orthopedics, and anti-adhesion and hemostasis, with key products such as intraocular lenses, hyaluronic acid dermal fillers, and sodium hyaluronate injections. It is headquartered in Shanghai, China, and was founded in 2007.
more
•05 Aug 2026 02:53

Primer: Shanghai Haohai Biological Technology (6826 HK) - Aug 2026

Shanghai Haohai Biological Technology is a diversified medical device and pharmaceutical company with leading positions in several high-growth...

Share
•26 May 2025 12:04

A/H Premium Tracker (To 23 May 2025):  AH Premia Contract, H Premia Names Perform Best; Batteries!

AH Premia contract again. Interestingly, the best performing tranche of discount was stocks where Hs trade at a premium to As. BYD squeezed. CATL a...

Logo
948 Views
Share
•19 Apr 2026 08:30

APAC Healthcare Weekly (April 19) – Fosun Pharma, Remegen, Daiichi Sankyo, Astellas Pharma, Telix

FDA granted Priority Review to Daiichi Sankyo’s I-DXd. Astellas Pharma initiates Phase 3 study for setidegrasib. Telix and Regeneron...

Logo
467 Views
Share
bullish•Quantitative Analysis
•20 Sep 2026 10:20

A-H Premium Weekly (Sep 18th): Minsheng Bank, Air China, Ceb Bank, China East Air

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Minsheng Bank, Air China, Ceb Bank, China East Air.

Logo
95 Views
Share
bullish•Quantitative Analysis
•30 Aug 2026 10:15

A-H Premium Weekly (Aug 28th): Gwmotor, China Mobile, Remegen, Fuyao Glass, Minsheng Bank

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Gwmotor, China Mobile, Remegen, Fuyao Glass, Minsheng Bank.

Logo
106 Views
Share
x